Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 31:13:42.
doi: 10.1186/1471-2407-13-42.

The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

Jian Zhang  1 , Zhen Jia, Joseph Ragaz, Ying-Jian Zhang, Min Zhou, Yong-Ping Zhang, Gang Li, Bi-Yun Wang, Zhong-Hua Wang, Xi-Chun Hu
Affiliations

The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

Jian Zhang et al. BMC Cancer. .

Abstract

Background: Whether PET scan maximum standard uptake value (SUVmax) could differentiate luminal A from luminal B and help predict the survival of metastatic breast cancer (MBC) patients with luminal subtype is still unknown and need to be investigated.

Methods: 305 MBC patients with luminal subtypes were screened with PET/CT. Eligible patients were prospectively followed up.

Results: In total, 134 patients were eligible for this study. SUVmax was significantly related to the number of metastatic sites and presence of visceral metastasis on univariate analysis. SUVmax could not effectively differentiate patients with luminal A from luminal B subtype. Although luminal subtype at diagnosis could predict the relapse-free interval, it could not predict progression-free survival (PFS) or overall survival (OS) after developing relapse. In contrast, SUVmax was predictive of both PFS and OS and this effect was maintained in multivariate COX regression model.

Conclusions: SUVmax of MBC did not correlate with molecular subtypes of primary tumor. While molecular subtype may be a valuable prognostic factor at primary diagnosis of breast cancer, the SUVmax, rather than molecular subtype, does have a potential to predict independently in multivariate analysis for the PFS and OS in patients with metastatic disease of luminal subtype.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient screening and inclusion diagram.
Figure 2
Figure 2
The receiver operator characteristic (ROC) curve for SUVmax in the differential diagnosis of luminal A subtype from luminal B subtype. The curve describes the association between sensitivity and specificity at different thresholds. The area under the curve (AUC) was 0.516.
Figure 3
Figure 3
Luminal subtypes and Baseline SUVmax as prognostic variables in survival curves. (A) Relapse-free interval (RFI) curves according to Luminal types. (B) Overall survival 1 (OS1) curves according to Luminal types. (C) Progression-free survival (PFS) curves according to Luminal types. (D) Overall survival 2 (OS2) curves according to Luminal types. (E) PFS curves according to Baseline SUVmax tertiles. (F) OS2 curves according to Baseline SUVmax tertiles.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 2012;36(3):237–248. doi: 10.1016/j.canep.2012.02.007. - DOI - PubMed
    1. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M. et al.Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100(16):1179–1183. doi: 10.1093/jnci/djn233. - DOI - PMC - PubMed
    1. Mariani G. New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. Ann Oncol. 2005;16(Suppl 2):i191–i194. - PubMed
    1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS. et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–10874. doi: 10.1073/pnas.191367098. - DOI - PMC - PubMed
    1. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S. et al.Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–2502. doi: 10.1001/jama.295.21.2492. - DOI - PubMed